Europe expansion Curavit is rapidly expanding into Europe through the acquisition of Lindus Health assets and new European offices, presenting a sales window to offer unified multinational trial execution and regional capabilities to sponsors seeking cross-continental studies.

Decentralized trial focus The company emphasizes decentralized, hybrid, and traditional trial models, presenting a selling point to life sciences firms aiming to accelerate enrollment, improve participant engagement, and streamline data collection across diverse sites.

Single-partner multi-region With a strategy to run multi-region studies under one partner, Curavit can target sponsors looking to reduce vendor fragmentation and achieve consistent execution across North America and Europe.

HEOR and digital therapeutics Investments in Health Economics and Outcomes Research and HEOR services position Curavit to upsell value-based outcomes work for digital therapeutics and pharma programs seeking robust economic endpoints.

Scale and efficiency As a lean CRO with a proven model for faster, more predictable enrollment and high-quality longitudinal data, Curavit offers an attractive efficiency proposition for sponsors facing long trial timelines and data gaps.